The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Risk factors for progression in MPNs
In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses risk factors for progression in myeloproliferative neoplasms (MPNs), highlighting the important role that genetic aberrations and driver mutations play in disease. Dr Verstovsek first comments on mutations that play a role in disease progression, and then discusses other factors that influence patient outcome and the importance of early intervention. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
